ATTO net loss $39.3M in 1H 2026; IPO funds runway to 2030
ATTO reported net loss of $39.3 million for the first half of 2026, driven by a 40% rise in R&D expenses. The company’s August 2026 IPO raised $305.4 million in net proceeds, extending its cash runway into 2030.
Story updates
08:25:36 PM UTC
SquawkNews
Preliminary clinical proof of concept achieved for lead candidate in pruritic diseases, with multiple pipeline programs advancing toward clinical trials. IPO proceeds of $332.4 million extend cash runway into 2030, supporting robust R&D investment and operational growth.Original document: Attovia T…
Net loss increased to $39.3 million for the first half of 2026, driven by a 40% rise in R&D expenses as the pipeline advanced.
The company completed an IPO in August 2026, raising $305.4 million in net proceeds, extending its cash runway into 2030.Original document: Attovia Therapeutics, Inc. [ATTO…